Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106

Apellis Pharmaceuticals (APLS) PT Raised to $114 at BofA Securities

BofA Securities analyst Tazeen Ahmad raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $114.00 (from $112.00) while maintaining a Buy rating.... More

Apellis Pharmaceuticals (APLS) PT Raised to $90 at Stifel

Stifel analyst Annabel Samimy raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $90.00 (from $75.00) while maintaining a Buy rating.... More

Apellis Pharmaceuticals (APLS) PT Raised to $110 at Needham & Company

Needham & Company analyst Joseph Stringer raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $110.00 (from $80.00) while maintaining a Buy rating.... More

Apellis Pharmaceuticals (APLS) PT Raised to $156 at Raymond James

Raymond James analyst Steven Seedhouse raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $156.00 (from $139.00) while maintaining a Strong Buy rating.... More

Apellis Pharmaceuticals (APLS) PT Raised to $76 at Wells Fargo

Wells Fargo analyst Derek Archila raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $76.00 (from $55.00) while maintaining a Equal Weight rating.... More

Apellis Pharmaceuticals (APLS) PT Raised to $81 at Credit Suisse

Credit Suisse analyst Tiago Fauth raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $81.00 (from $70.00) while maintaining a Neutral rating.... More

After-hours movers: Apple gains on surprise beat, Lyft tumbles

After-Hours Stock Movers:

Trupanion (NASDAQ: TRUP) 27% LOWER; reported Q1 EPS of ($0.60), $0.33 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $256.3 million versus the consensus estimate of $251.68 million.

Carvana Co. (NYSE: CVNA) 24% HIGHER; reported Q1 Revenue for the quarter at $2.61 billion versus the consensus estimate of $2.66 billion. The company expects to achieve positive adjusted EBITDA in Q2.

Clearfield, Inc. (NASDAQ:... More

Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 10c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of $1.56, $0.10 worse than the analyst estimate of $1.66. Revenue for the quarter came in at $44.84 million versus the consensus estimate of $26.1 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.